Liquidia Technologies has reached a global settlement with United Therapeutics, resolving all six ongoing lawsuits between the companies. This agreement ensures that YUTREPIA, Liquidia's inhaled treatment for pulmonary arterial hypertension (PAH), remains available to patients without interruption. Liquidia will pay a total of $380.7 million in installments through 2027 and plans to continue advancing its clinical programs. The settlement allows Liquidia to focus on growing YUTREPIA's market presence and developing new treatments for related conditions.
Liquidia Technologies' global settlement with United Therapeutics is presented here with relevant market data for context. For readers following the health sector, as of Oct 14, 2026 03:41 WIB, out of 128 priced US health stocks on Pluang, 29 rose and 99 fell. Notably, Canopy Growth Corp (CGC) traded at USD 0.76 with a 7.53% decline and a strong buy order activity of 97%, contrasting with BioNTech SE (BNTX) at USD 89.78 down 6.32% and a near-even sell/buy split of 53%/47%. Sana Biotechnology (SANA) also declined 6.87% at USD 2.44 with 92% buy orders, showing varied investor interest across these assets.
Nvidia CEO Jensen Huang has reaffirmed his long-standing forecast that global spending on AI infrastructure will surge to between $3 trillion and $4 trillion by 2030. This projection highlights the massive growth potential in the AI sector, driven by...
Targa Resources Corp. announced a quarterly cash dividend of $1.25 per common share for Q3 2026, payable on November 17, 2026, to shareholders of record as of October 30, 2026. The company will release its Q3 2026 financial results before market open...
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
